Andreas Obermair, MD, on Treating Endometrial Adenocarcinoma With a Levonorgestrel Intrauterine Device
SGO 2021 Virtual Annual Meeting on Womens Cancer
Andreas Obermair, MD, of the University of Queensland and Queensland Centre for Gynaecological Cancer Research, discusses data on a hormonal IUD used to treat women with the precursor lesion endometrial hyperplasia with atypia (EHA) and those with stage I endometrial adenocarcinoma (EAC). At 6 months, the data showed a complete pathologic response in 82% of patients with EHA and in 43% of those with EAC (ID# 10244).
The ASCO Post Staff
Lauren Thomaier, MD, of the University of Minnesota, discusses the genetic variants found to be associated with an increase in chemotherapy-induced neuropathy symptoms in a cohort of gynecologic cancer survivors. Combining these variants with clinical characteristics may provide an important treatment tool (ID# 10253).
The ASCO Post Staff
Brittany A. Davidson, MD, of Duke University, discusses the development and validation of the GO-POP model (Gynecologic Oncology Predictor of Postoperative opioid use), an individualized patient-centered predictive tool designed to help avoid overprescribing pain medications (ID# 10253).
The ASCO Post Staff
Vicky Makker, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III findings showing that lenvatinib plus pembrolizumab may improve overall and progression-free survival, as well as overall response rate, compared with treatment of physician’s choice for advanced endometrial cancer. These results were achieved regardless of mismatch repair status following platinum-based chemotherapy (ID #10191).
The ASCO Post Staff
Edward L. Trimble, MD, MPH, of the National Cancer Institute, discusses the World Health Organization’s global strategy to speed the elimination of cervical cancer through vaccination, screening, treatment, and training for multidisciplinary teams in gynecologic oncology care. This marks the first time that 194 countries have committed to such an effort (ID # 10203).
The ASCO Post Staff
Alice P. Barr, MD, of the Carolinas Medical Center and Levine Cancer Institute, discusses results from a retrospective study, which showed that progression-free and overall survival appeared to be no different with open surgery and minimally invasive surgery for interval debulking after neoadjuvant chemotherapy in women with advanced epithelial ovarian cancer. Perioperative outcomes also seemed to be superior with minimally invasive surgery (ID #10209).